报价延迟最少15分钟:2026/07/27 05:37 EDT
盘前时段
|
||||
|
235.02 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
235.44
|
|
|
| 价值评估 |
|
盈利(现时/预测)
10.71/18.41
|
|
企业价值
27.38B
|
| 资产负债 |
|
每股账面净值
-11.77
|
| 现金流量 |
|
现金流量率
0.12
|
| 损益表 |
|
收益
13.64B
|
|
每股收益
185.58
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. |
